ArticleOPEN ACCESS

Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trial

Journal of Infection
DOI: 10.1016/j.jinf.2024.106120
8Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

This article is free to access.

Cite

CITATION STYLE

APA

Hites, M., Lapique, E. L., Massonnaud, C. R., Belhadi, D., Jamard, S., Goehringer, F., … Ader, F. (2024, March 1). Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trial. Journal of Infection. W.B. Saunders Ltd. https://doi.org/10.1016/j.jinf.2024.106120

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free